1. Home
  2. EOI vs DBVT Comparison

EOI vs DBVT Comparison

Compare EOI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

EOI

Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

HOLD

Current Price

$19.70

Market Cap

817.2M

Sector

Finance

ML Signal

HOLD

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

HOLD

Current Price

$12.44

Market Cap

850.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOI
DBVT
Founded
N/A
2002
Country
United States
France
Employees
N/A
90
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
817.2M
850.9M
IPO Year
2004
2014

Fundamental Metrics

Financial Performance
Metric
EOI
DBVT
Price
$19.70
$12.44
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$32.04
AVG Volume (30 Days)
55.1K
269.8K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.26
EPS
N/A
N/A
Revenue
N/A
$5,636,000.00
Revenue This Year
N/A
$35.04
Revenue Next Year
N/A
$2,360.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
35.77
52 Week Low
$18.04
$8.86
52 Week High
$21.44
$26.19

Technical Indicators

Market Signals
Indicator
EOI
DBVT
Relative Strength Index (RSI) 42.57 40.13
Support Level $19.39 N/A
Resistance Level $20.20 $14.90
Average True Range (ATR) 0.19 0.53
MACD -0.05 -0.10
Stochastic Oscillator 32.93 27.91

Price Performance

Historical Comparison
EOI
DBVT

About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest

Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: